乳腺癌证候学特点研究
|
摘要
乳腺癌是女性最常见的恶性肿瘤之一,是各个国家共同关心的问题。就世界范围而言,其发病率呈上升趋势,它已成为世界上许多妇女的头号杀手。乳腺癌治疗包括手术、放疗、化疗、内分泌、生物治疗、中医药治疗等几种方式。本研究目的在应用中西医结合方式探讨乳腺癌的发病、进展及转归,将中医证候学要素与肿瘤标志物、受体、转移情况相结合,揭示其内在相关性,以指导治疗临床辨证治疗。
目的:探索乳腺癌中医证候特点
方法:采用回顾性研究方法,总结乳腺癌患者的证型分布特点,并归纳各证候要素与肿瘤标志物、受体、转移情况等各因素,对病例计数资料采用SPSS 15.0软件r×c x~2检验方法,从中发现乳腺癌中医证候要素与肿瘤标志物、受体、转移的相关性。
研究结果:
1、纳入病例多为应用多种治疗手段的中晚期女性乳腺癌患者,均表现为虚实夹杂的证候特点。实证以肝郁气滞、痰凝、血瘀证候为主。虚证以阳气虚证候为主。在阳气虚兼加证中以阳气虚+痰湿+血瘀证多见,其次分别为阳气虚+肝郁气滞+痰湿、阳气虚+肝郁气滞+血瘀、阳气虚+痰湿证。阴血虚兼加证中,以阴血虚+肝气郁滞、阴血虚+痰湿、阴血虚+血瘀证较多见。
2、痰湿、血瘀证候要素易出现CA125、CA153升高趋势,其阳气虚与阴血虚证候要素与肿瘤标记物的异常升高无相关性。
3、ER、PR的表达与肝郁气滞、痰湿、血瘀、阳气虚、阴血虚等各证候要素均无明显相关性。但分布比例上看阳气虚患者在ER、PR阳性表达率较阴血虚患者更高。
4、痰湿、血瘀证候要素易出现腋窝淋巴结转移、肝转移、肺转移趋势;阳气虚证候易出现肝转移趋势;阳气虚与阴血虚证候与腋窝淋巴结、肺转移无相关性。
5、各证候要素与骨转移无相关性。
结论:
(1)经过多种治疗手段的中晚期乳腺癌患者往往存在本虚标实的证候类型特点,各证候要素中虚证以阳气虚主,实证以肝郁气滞、痰湿、血瘀为主。
(2)痰湿、血瘀证候要素影响CA125、CA153肿瘤标记物的表达。
(3)ER、PR的表达与肝郁气滞、痰湿、血瘀、阳气虚、阴血虚等各证候要素均无明显相关性。但分布比例上看阳气虚患者在ER、PR阳性表达率较阴血虚患者更高。
(4)痰湿、血瘀证候患者腋窝淋巴结转移、肝转移、肺转移的危险性更高,肝郁气滞证候患者转移危险性较低;阳气虚候肝转移危险性更高。
Breast cancer is one of the most common malignant cancers of women,and is the international issue worldwide.Its incidence is rising,and has beco me the number one killer of women in many parts of the world.The treatment s of breast cancer include surgery,radiotherapy,chemotherapy,endocrine,b iological treatment,Chinese medicines and so on.The purpose of this study is to explore the incidence、the progress and outcome of breast cancer in t he method of Chinese and Western medicine.This study reveals the relationsh ip of Chinese medicine syndromes,tumor markers、receptors and the metastas is of breast cancer.It also provides a very good guider to the usage of Chi nese Medicine,to determine the efficacy and how to delay theprogress of th e cancer.
Purpose:to study the characteristic of Chinese Medicine Sydromes in pa tients suffing from breast cancer.
Methods:This study retrospectively analyzed syndrome type distribution of the breast cancer in patients(a total of 86 patients in this group) who are confirmed diagnosis,and summarized the relationship of Chinese Medicine syndromes,tumor markers,receptors and the metastasis of breast cancer.The factors were dated and were assessed by spss 15.0 software.(RXC) X~2 test was used to evaluate the relationship between them,so as to find the prevention and treatment methods of tumors rationally,meanwhile to improve the efficacy of clinical treatments.
Results:
1、The patients involved have received many medthods.The excess syndromes are mainly liver qi depression,static blood and phlegm.The deficiency syndrome is Yang qi deficiency,ln yang qi deficiency syndromes,static blood-phlegm syndrome is quite common,liver qi depression-phlegm syndrome and phlegm-dampness syndrome are sequent.In yin blood deficiency syndromes,liver qi depression is common,depression-phlegm and static blood syndromes are sequent.
2、Patients with phlegm-dampness syndrome and static blood syndrome tendly have high CA125 and CA153,while yang qi deficiency and yin blood deficiency syndromes is irrelevant with the rising of tumor markers.
3、ER and PR are irrelevant with liver qi depression,phlegm-dampness,blood stasis,Yang qi deficiency,yin blood deficiency syndromes.However,the distribution and the proportion of patients with Yang qi deficiency are higher than that in patients with yin blood deficiency in the ER,PR positive expression.
4、Patients with phlegm-dampness and blood stasis syndromes have a higher rate with lymph node metastasis,liver metastasis and lung metastasis.Patients with yang qi deficiency syndrome tendly have a higher rate of liver of matastasis.Patients with yang qi deficiency syndrome and yin blood deficiency syndromes are irrelevant with lymph node metastasis and lung metastasis.
Conclusion:
1、The breast cancer patients who use a variety of treatment is often exist the characteristic of deficiency-excess complex syndrome.The main deficiency is the yang qi defiency.The main excess syndromes are liver qi depression, phlegm-dampness and blood stasis syndromes.
2、phlegm-dampness syndrome and blood stasis syndrome effect CA125,CA153 tumor marker expression.
3、ER,PR expression had no significant correlation with.the liver qi depression,phlegm-dampness,blood stasis,yang qi deficiency,yin blood deficiency Syndromes.
4、The breast cancer patients with phlegm-dampness and blood stasis syndromes have a a higher positive rate with lymph node metastasis,liver metastasis and lung metastasis.Patients with liver qi depression,opposite.Patients with yang deficiency syndrome have a higher rate of liver of matastasis.
目的:探索乳腺癌中医证候特点
方法:采用回顾性研究方法,总结乳腺癌患者的证型分布特点,并归纳各证候要素与肿瘤标志物、受体、转移情况等各因素,对病例计数资料采用SPSS 15.0软件r×c x~2检验方法,从中发现乳腺癌中医证候要素与肿瘤标志物、受体、转移的相关性。
研究结果:
1、纳入病例多为应用多种治疗手段的中晚期女性乳腺癌患者,均表现为虚实夹杂的证候特点。实证以肝郁气滞、痰凝、血瘀证候为主。虚证以阳气虚证候为主。在阳气虚兼加证中以阳气虚+痰湿+血瘀证多见,其次分别为阳气虚+肝郁气滞+痰湿、阳气虚+肝郁气滞+血瘀、阳气虚+痰湿证。阴血虚兼加证中,以阴血虚+肝气郁滞、阴血虚+痰湿、阴血虚+血瘀证较多见。
2、痰湿、血瘀证候要素易出现CA125、CA153升高趋势,其阳气虚与阴血虚证候要素与肿瘤标记物的异常升高无相关性。
3、ER、PR的表达与肝郁气滞、痰湿、血瘀、阳气虚、阴血虚等各证候要素均无明显相关性。但分布比例上看阳气虚患者在ER、PR阳性表达率较阴血虚患者更高。
4、痰湿、血瘀证候要素易出现腋窝淋巴结转移、肝转移、肺转移趋势;阳气虚证候易出现肝转移趋势;阳气虚与阴血虚证候与腋窝淋巴结、肺转移无相关性。
5、各证候要素与骨转移无相关性。
结论:
(1)经过多种治疗手段的中晚期乳腺癌患者往往存在本虚标实的证候类型特点,各证候要素中虚证以阳气虚主,实证以肝郁气滞、痰湿、血瘀为主。
(2)痰湿、血瘀证候要素影响CA125、CA153肿瘤标记物的表达。
(3)ER、PR的表达与肝郁气滞、痰湿、血瘀、阳气虚、阴血虚等各证候要素均无明显相关性。但分布比例上看阳气虚患者在ER、PR阳性表达率较阴血虚患者更高。
(4)痰湿、血瘀证候患者腋窝淋巴结转移、肝转移、肺转移的危险性更高,肝郁气滞证候患者转移危险性较低;阳气虚候肝转移危险性更高。
Breast cancer is one of the most common malignant cancers of women,and is the international issue worldwide.Its incidence is rising,and has beco me the number one killer of women in many parts of the world.The treatment s of breast cancer include surgery,radiotherapy,chemotherapy,endocrine,b iological treatment,Chinese medicines and so on.The purpose of this study is to explore the incidence、the progress and outcome of breast cancer in t he method of Chinese and Western medicine.This study reveals the relationsh ip of Chinese medicine syndromes,tumor markers、receptors and the metastas is of breast cancer.It also provides a very good guider to the usage of Chi nese Medicine,to determine the efficacy and how to delay theprogress of th e cancer.
Purpose:to study the characteristic of Chinese Medicine Sydromes in pa tients suffing from breast cancer.
Methods:This study retrospectively analyzed syndrome type distribution of the breast cancer in patients(a total of 86 patients in this group) who are confirmed diagnosis,and summarized the relationship of Chinese Medicine syndromes,tumor markers,receptors and the metastasis of breast cancer.The factors were dated and were assessed by spss 15.0 software.(RXC) X~2 test was used to evaluate the relationship between them,so as to find the prevention and treatment methods of tumors rationally,meanwhile to improve the efficacy of clinical treatments.
Results:
1、The patients involved have received many medthods.The excess syndromes are mainly liver qi depression,static blood and phlegm.The deficiency syndrome is Yang qi deficiency,ln yang qi deficiency syndromes,static blood-phlegm syndrome is quite common,liver qi depression-phlegm syndrome and phlegm-dampness syndrome are sequent.In yin blood deficiency syndromes,liver qi depression is common,depression-phlegm and static blood syndromes are sequent.
2、Patients with phlegm-dampness syndrome and static blood syndrome tendly have high CA125 and CA153,while yang qi deficiency and yin blood deficiency syndromes is irrelevant with the rising of tumor markers.
3、ER and PR are irrelevant with liver qi depression,phlegm-dampness,blood stasis,Yang qi deficiency,yin blood deficiency syndromes.However,the distribution and the proportion of patients with Yang qi deficiency are higher than that in patients with yin blood deficiency in the ER,PR positive expression.
4、Patients with phlegm-dampness and blood stasis syndromes have a higher rate with lymph node metastasis,liver metastasis and lung metastasis.Patients with yang qi deficiency syndrome tendly have a higher rate of liver of matastasis.Patients with yang qi deficiency syndrome and yin blood deficiency syndromes are irrelevant with lymph node metastasis and lung metastasis.
Conclusion:
1、The breast cancer patients who use a variety of treatment is often exist the characteristic of deficiency-excess complex syndrome.The main deficiency is the yang qi defiency.The main excess syndromes are liver qi depression, phlegm-dampness and blood stasis syndromes.
2、phlegm-dampness syndrome and blood stasis syndrome effect CA125,CA153 tumor marker expression.
3、ER,PR expression had no significant correlation with.the liver qi depression,phlegm-dampness,blood stasis,yang qi deficiency,yin blood deficiency Syndromes.
4、The breast cancer patients with phlegm-dampness and blood stasis syndromes have a a higher positive rate with lymph node metastasis,liver metastasis and lung metastasis.Patients with liver qi depression,opposite.Patients with yang deficiency syndrome have a higher rate of liver of matastasis.
引文
[1]杨玲,李连弟,陈育德.中国2000年及2005年恶性肿瘤发病死亡的估计与预测.中国卫生统计,2005,22(4):218-222
[2]李春杰,魏品康,施俊,刘龙,巨大维.恶性肿瘤从痰论治的研究思路与方法.解放军保健医学杂志,2007,9(4):241-242
[3]杨浩.癌症论.中国民族民间医药,2008,17(3):57-58
[4]陈健民.癌症患者血液高凝状态与活血化瘀治疗.中国中西医结合杂志,1985,5(2):89-91
[5]薛晓红,陈红风,陆德铭.陆德铭教授治疗乳房病的学术思想及临证经验.中医药研究,2002,18(5):1-2
[6]徐力.王居祥主任医师治疗乳腺癌经验举隅.南京中医药大学学报,2007,23(1):54
[7]李树玲.乳腺肿瘤学.科学技术文献出版社,2000,535-537
[8]尚德俊.新编中医外科学.济南出版社,1995,103
[9]陆德铭.实用中医乳房病学.上海中医学院出版社,1993,29
[10]郁仁存.中医肿瘤学(上册).科学出版社,1997
[11]王玉章.乳岩.北京中医,1993,(3):59-60
[12]周宝琴.治疗乳腺癌的临床体会.吉林中医药,1985,(4):17-18
[13]田劭丹,李忠.乳腺癌的中西医结合诊治.中国临床医生杂志,2007,35(5):17-18
[14]王宗发.乳腺癌临床分型证治.中华现代医学与临床,2005,3(2):69-70
[15]刘胜,陆德铭,唐汉钧.302例乳腺癌术后患者辨证分型标准的临床研究.中国医药报,2004,19(11):666-668
[16]徐杰男,阙华发.乳腺癌术后患者241例辨证分型探析.浙江中医杂志2005,40(12):530-532
[17]唐汉钧.乳腺癌的中医临床与实验研究.中医药学刊,2003,21(2):168-172
[18]Anthoy L,David JK.Cancer,Coagulation,and Anticoagulation.Oncologist,1999,443
[19]唐汉钧.乳腺癌术后的临证思考.上海中医药杂志,2005,39(1):3-5
[20]司徒红林,陈前军,朱华宇.林毅教授辨治乳腺癌经验介绍.新中医,2008,40(7):5-6
[21]王晓戎,李平,吴志丽.肿瘤化疗后中医证候学特征调查研究.山东中医杂志,2006,25(1):18-20
[22]顾群浩,蔡照弟,张胜华.乳腺癌辨证分型与雌孕激素受体的相关性分析.辽宁中医杂志,2004,31(6):463-464
[23]孙红,李萍萍.乳腺癌中医证候分类与预后相关性的初步研究.中国中医基础医学杂志,2003,9(2):72-73
[24]李萍萍,孙红,史桂芝等.移植瘤的血液流变学与活血化瘀中药作用的研究.肿瘤,2000,20(3):44
[25]张瑾,吴咸中,李特.乳腺癌中西医结合辨证分型研究.中国中西医结合外科杂志, 2001,7(1):13-15
[26]PapantoniouVJ,SouvatzoglouMA,ValotassiouVJ,eta.1 Relationship of cell proliferation(Ki-67) to 99mTc2(V)DMSA uptake in breast cancer[J].Breast CancerRes,2004,6(2):56262
[27]Mast ronardi L,GuiducciA,Puzzilli F.Lack of correlation be-tween Ki267labelling index and tumor size ofanteriorpi2 tuitary adenomas.BMC Cancer,2001,31(12):1232130
[28]宋爱莉,殷玉琨.乳腺癌术前中医辨证与肿瘤增殖因子相关性研究.中华中医药学刊,2008,26(5):907-908
[29]郭俊骐,郭卉艳,李兵.名老中医石玉林治疗乳腺癌骨转移30例.吉林中医药,1998,(2):3-4
[30]李俊玉.癌毒的病因病机及临证治法的概念探析.江西中医药,2005,36(8):14-15
[31]卢雯平,林洪生.160例乳腺癌术后血行转移患者中医辨证分型的研究.临床肿瘤学杂志,2006,11(6):425-426
[32]秦海洗.唐汉钧教授治疗乳腺癌辨证思路与用药经验.中西医结合学报,2004,2(4):297-298
[33]欧阳华强,黄雯霞,刘鲁明.消瘕方治疗乳腺癌术后110例的临床观察.上海中医药杂志,2006,40(6):50-51
[34]许宇飞,张成智.乳腺癌 X 线征象与中医证型关系分析.中医药信息,1999,16(1):39-40
[35]张昌政,翠玲.肝郁痰凝型乳腺癌的钼靶 X 线表现及病理分析.山西中医,2006,22(6):50-51
[36]黄勇,张延伟,李健萍,李圆.乳腺癌 MR 征象与中医证型关系观察.新中医,2008,40(8):35-38
[37]周红,郭亚东等.中药治疗晚期乳腺癌9例报道.实用肿瘤学杂志,1998,2(1):59-60
[38]王庆才.蟾雄膏外敷治疗癌性疼痛103例.陕西中医,1993,14(5):195
[39]肖毅良,杨邵波.菊藻丸治疗乳癌术后转移的临床研究.中国中西医结合外科杂志,1998,4(5):202.
[40]刘抒玉,殷东风.中医药治疗乳腺癌92例临床观察.吉林中医药,2008,28(5):333-334
[41]吴少华,张促海,赵健斌.补骨脂素体内外抗癌活性的实验研究.中国中药杂志,1998,23(5):303
[42]赵勇,崔正言,张玲等.淫羊霍甙对人急性早幼粒白血病细胞分化的影响.中华肿瘤杂志,1997,19(1):53
[43]李薇,易永林.人参茎叶总皂甙对人白血病细胞株的诱导作用.山西白血病,1992:1(1):34
[44]刘胜.“乳宁冲剂”抑制 DMBA 诱发大鼠乳腺癌模型的实验研究.亚洲医药,1997,3(5):95
[45]孙斌,瞿伟菁,柏忠江.蒺藜皂苷对乳腺癌细胞 Bcap-37 的体外抑制作用.中药材,2003,26(2):104-106
[46]张维文,黎银燕,张贵平等.熊果酸诱导人乳腺癌细胞 MCF-7 凋亡的实验研究.中药材,2005,28(4):297-300
[47]曲志博,陈炜,郭化鑫等.三氧化二砷对乳腺癌作用的研究进展.中华实验外科杂志,2006,23(5):639-640
[48]余素清,刘京生,韩彩芝.复方绞股蓝提高乳腺癌患者 NK 细胞活性.中医药研究,1997,13(4):7-8
[49]杨丽萍,孙士玲.中药配合术前化疗治疗乳腺癌临床研究.河南中医学院学报,2004,4(19):40
[50]林军梅.补阳还五汤治疗乳腺癌术后上肢肿胀36例.浙江中医学院学报,1997,21(5):38
[51]樊风英,周松阳.补阳还五汤加减治疗乳腺癌术后上肢水肿19例体会.甘肃中医,2002,15(6):25-26
[52]王志华.中药治疗乳腺癌术后上肢肿胀30例.中国中西医结合外科杂志,2008,14(1):57-58
[53]孙鲁.复方丹参注射液静滴防治乳腺癌术后并发症的临床观察.山东医药,1999,39(24):55
[54]孙德娟,黄克江,鲍维珍.生肌玉红膏治疗乳腺癌术后皮瓣坏死26例体会.黑龙江医学,2006,30(7):553
[55]蔡炳,郭勤,郭智涛等.生肌玉红膏对乳腺癌术后皮瓣坏死溃疡的疗效观察.中医外治杂志,1997,(5):11
[56]洪宋贞,林毅,司徒红林.龟鹿二仙丹加味治疗乳腺癌化疗后骨髓抑制的研究.新中医,2005,37(1):32-34
[57]韩娅.健脾益肾中药防治乳腺癌放疗血液毒性作用的观察.中医药临床杂志,2005,17(1):25-26
[58]张宏,李国康.增髓汤对乳腺癌术后化疗改善骨髓抑制的研究.实用医学杂志,2005,21(13):1481-1482.
[59]李云著,李志革,黄秉琰.四磨汤治疗化疗所致的胃肠道症状27例总结.湖南中医杂志,1997,13(4):5
[60]吴雪卿,刘胜,高尚璞.乳宁Ⅱ号对 MCF-7 实验研究移植瘤的抑瘤作用及对乳腺癌相关蛋白的影响.中国中西医结合外科杂志,2004,10(2):99-102
[61]张永军,张在典等.中药熏洗防治希罗达所致手足综合征25例.现代中西医结合杂志,2008,17(10):1495
[62]李福莲,张克伟,张春生,高玲,菅福琴.自制中药洗剂防治乳腺癌化疗脱发30例效果观察.齐鲁护理杂志,2007,13(13):24-25
[63]张利伟,赵娟.中西医结合治疗放射性肺炎的临床研究.中国实用医药.2008,3(24):112-113
[64]廖震,胡春申.润肺清热方治疗放射性肺炎60例疗效观察.中国中医急症,2008,17(1):18-19
[65]黄智芬,黎汉忠,施智严等.逍遥散化疗并用治疗乳腺癌32例分析.中医药学刊,2003,21(6):1017
[66]徐力,龚蔚.疏肝化瘀解毒方联合 TE 方案治疗乳腺癌15例.南京中医药大学学报,2008,24(1):66-67
[67]孙靖中.中医药在乳腺癌围手术期的应用研究.华夏医药,2006,33(8):25
[68]郝淑芳.中药配合来曲唑治疗晚期乳腺癌临床观察.中医药学刊,2004,22(11):2089
[69]袁灿宇,张丽蓓.CMFA 化疗方案配合中药治疗晚期乳腺癌31例近期疗效观察.河南中医,2004,24(5):42-43
[70]张洪亮,王宁.乳腺癌辨治篡要.新疆中医药,2001,19(3):3-4
[71]欧阳华强,黄雯霞,刘鲁明.乳腺癌肝转移治疗进展.实用癌症杂志,2005,20(4):442-445
[72]周菊英.中西医结合治疗晚期乳腺癌86例临床观察.山西中医,2000,16(6):30-31
[73]冯春霞,梁蔚文.陈玉坤运用中医药治疗肿瘤经验析义.辽宁中医杂志,2005,32(9),883-884
[1]Bonadonna G,Valagussa P,BrambillaC,et al.Primary chemotherapy in operable breast cancer:Eight-year experience at the Milan Cancer Institute.J Clin Oncol,1998,16:93-100
[2]EllisP,Smith I,Ashley S,et al.Clinical prognostic and predictive factors for primary chemotherapy in operable breast cancer.J Clin Oncol,1998,16:107
[3]Van Praagh I,Cure H,Leduc B,et al.Efficacy of a primary chemotherapy regimen combining vinorelbine,epirubicin,and methotrexate(VEM) as neoadjuvant treatment in 89 patients with operable breast cancer.Oncologist,2002,7(5):418-423
[4]Bonadonna G,Valgussa P,Moliterni A,et al.Adjuvant cyclophosphamide,methotrexate and fluorouracil in node-positive breast cancer:the results of 20 year follow-up.N Engl J Med,1995,332:901-906
[5]Levine MN,Bramwell VH,Pritchard KI,et al:Randomized trial of intensive cyclophosphamide,epirubicin and fluorouracil chemotherapy compared with cyclophosphamide,methotrexate and fluorouracil in premenopausal women with node-positive breast cancer.National Cancer Institute of Canada Clinical Trials Group.J Clin Oncol,1998,16:2651-2658
[6]Henderson IC,Berry DA,Demetri GD,et al.Imp roved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer[J].J Clin Oncol,2003,21(6):976-983
[7]Henderson IC,Berry DA,Demetri GD,et al.Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an ad-juvant chemotherapy regimenforpatientswithnode-positive primary breastcancer.J Clin Oncol,2003,21(6):976-983
[8]MamounasEP,BryantJ,Lembersky B,etal.Paclitaxelafterdoxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer:results from NSABP B-28.JClin Oncol,2005,23(16):3686-3696
[9]Boer K,Lang I,Juhos E,et al.Adjuvant therapy ofbreast cancer with docetaxel-containing combination (TAC).Pathol OncolRes,2003,9(3):166-169
[10]Marc LC,Donstance C,et al.Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer:First Report on Intergroup Trial CALGB 9741.J Clin Oncol,2003,21:1431-149
[11]Sledge MD,Oneil A,Thor AD,et.al.Pilot trial of paclitaxel-Herceptin adjuvant therapy for early stage breast cancer(E2198).Breast cancer Res Treat,2001,69:209
[12]Jones SE,Erban J,Overmoyer B,et al.Randomized phaseⅢ study of docetaxelcompared withpaclitaxel inmetastaticbreastcancer.JClin Oncol,2005,23(24):5542-5551
[13]Blum JL,Jones SE,Buzdar AU,et al.Multicenter phase Ⅱ study of capecitabinein paclitaxel-refractory metastaticbreastcancer.Clin Oncol,1999,17(2):485-493
[14]Blackstein M,Vogel CL,Ambinder R,et al.Gemcitabineas first-line therapyin patients with metastatic breastcancer:a phase Ⅱ trial.Oncology,2002,62(1):2-8
[15]杨军丛,曹月辉,苑丽华,陈忠云,李志霞.EAP 方案治疗晚期乳腺癌38例的临床观察.中国实用医药,2007,2(4):37
[16]王佳玉,徐兵河,张频,李青.紫杉醇联合顺铂治疗57例晚期乳腺癌的临床疗效分析.中华肿瘤防治杂志,2007,14(9):695-697
[17]王红.紫杉醇联合阿霉素治疗晚期乳腺癌疗效观察.中国肿瘤临床与康复,2007,14(1):50-51
[18]刘天亮,吴云.多西紫杉醇联合顺铂治疗晚期乳腺癌21例分析.中国误诊学杂志,2008,8(3).707-708
[19]王朝阳,杨帆,李桂生,黄海欣.泰索帝联合顺铂治疗26例葸环类耐药性晚期乳腺癌临床观察.实用医学杂志,2008,24(1):102-103
[20]吴星娆.卡培他滨在乳腺癌治疗中的临床应用.国际肿瘤学杂志2007,34(3):210-212
[21]李文欢.卡培他滨单药治疗葸环类和紫杉醇类耐药的晚期乳腺25例.中华肿瘤防治杂志,2007,14(3):216-217
[22]Seidman AD.Gemcitabine as single-agent therapy in themanage-ment of advanced breast cancer.Oncology,2001,15(2)(Supp13):11-14
[23]张志强,江泽飞,宋三泰.吉西他滨在乳腺癌化疗中的临床应用.国外医学肿瘤学分册,2003,30(2):132-135
[24]Mohran TZ.Gemcitabine and Cisplatin combination chemothera-py as a first-line treatment in patients with metastatic breastcance.JEgyptNatl Canc Inst,2004,16(1):8-14
[25]NagourneyRA,Link JS,Blitzer J,et al Gemcitabline plus cispla-tin repeating doublet therapy in previously treated,relapsed breast cancer patients.JClinOnco,12000,18(11):224-2249
[26]徐兵河,李凯,刘端琪.吉西他滨联合顺铂治50例蒽环类耐药的晚期乳腺癌.中国癌症杂志,2003,13(6):579-81
[27]刘明恒,陈旭.吉西他滨联合顺铂治疗 HER2 阳性转移性乳腺癌疗效观察.实用癌症杂志,2007,22(1):75-76
[28]黄普文,卢凯华,束永前,王榕生,朱陵君,王建,刘凌翔,穆庆霞.以吉西他滨为主的联合化疗方案治疗晚期乳腺癌的疗效评价.临床肿瘤学杂志,2007,12(2):94-96
[29]蓝玉宏,魏巍,长春瑞滨联合顺铂治疗晚期乳腺癌的疗效及毒副反应观察.现代预防医学,2007,34(4):879-880
[30]李宗宪,刘秀萍,丰建萍。NP 方案治疗转移性乳腺癌临床观察。中国肿瘤临床与康复,2007,14(1):53-55
[31]张爱琴,郭根法.去甲长春碱联合顺铂治疗转移性乳腺癌.癌症,2001,20(12):1408-1410
[32]孙燕,张湘如,张和平.去甲长春花碱Ⅲ期临床试用结果.中国新药杂志,1998,7(4):262-265
[33]唐域.NP 方案治疗晚期乳腺癌临床观察.WorldHealthDigest,2008,5(3):67-68
[34]EBCTCG(Early Breast Cancer Trialists Collaborative Group) Early Breast Cancer Trialists Collaborative Group.Tamoxifen for early breast cancer:an overview of the randomized trials.Lancet,1998,351:1451-1467
[35]Albain KS,Green SJ,Racsin PM,et al.Adjuvant chemohormonal therapy for primary breast cancer should be sequential inwtead of concurrent:Initial results from intergroup trail 0100(SWOG-8814).Proc AM Soc Clin Oncol,2002,21:37
[36]ODRegan R M.Chemoprevention of breast cancer.Lancet,2006,367(9520):1382-1383
[37]Nabholtz J M,Buzdar A,Pollak M,et al.Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women:results of a North American multicenterrandomized trial,Arimidex Study Group.J Clin Oncol,2000,18(22):3758-3767
[38]Howell A,Cuzick J,Baum M,et al.Results of the ATAC(arimidex,tamoxifen,alone or in combination) trial after completion of 5 yearsD adjuvant treatment for breast cancer.Lancet,2005,365(9453):60-62
[39]Jakesz R,Jonat W,Gnant M,et al.Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 yearsD adjuvant tamoxifen:combined results Of ABCSG trial 8 and ARNO 95trial.Lancet,2005,366(9484):455-462
[40]Mouridsen H,Gershanovich M,Sun Y,et al.Superior efficacy of letrozoleversus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer:results of a phase Ⅲstudy of the International Letrozole Breast Cancer Group,J ClinOncol,2001,19(10):2596-2606
[41]Thurlimann B,Keshaviah A,Coates A S,et al.A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.N Engl J Med,2005,353(26):2747-2757
[42]Goss P E,Ingle J N,Martino S,et al.Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer:updated findings from NCIC CTG MA 17.J Natl Cancer Inst,2005,97(17):1262-1271
[43]Paridaens R,Dirix L,Lohrisch C,etal.Mature results of a randomized phase Ⅱ multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer.Ann Oncol,2003,14 (9):1391-1398
[44]Milla Santos A,Milla L,Portella J,et al.Anastrozole versus ta-moxifen as first-line therapy in postm enopausal patients with hormone-dependent advanced breast cancer,-a prospective,random-ized,phaselllstudy.Am J Clin Oncol,2003,26(3):317-322
[45]Thurlimann B,Hess D,Koberle D,et al..Anastrozole(Arimidex)versus tamoxifen as first-line therapy in postm enopausal women with advanced breast cancer:results of the double-blind Crossover SAKK trial 21/9522a sub2study of the TARGET (Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability)trial.Breast Cancer Res Treat,2004,85(3):247-254
[46]BuzdarA,Douma J,DavidsonN,et al.Phase HI,multicenter,dou-ble-blind.randomized study of letrozole,an aromatase inhibitor,for advanced breast cancer versus megestrol acetate.J Clin On-col,2001,19(14):2234-2244
[47]Paridaens R,Dirix L,Lohrisch C,et al.Mature results of a ran-domized phase Ⅱ multicenter study of exemestane versus tamox-ifen as first-line hormone therapy for postmenopausal women-with metastatic breast cancer.Ann Oncol,2003,14(9):1391-1398
[48]Lonning PE,Bajetta E,Murray R,etal.Activity of exemestane in metastatic breast cancer after failure of nonsteroidal arom atase inhibitor:a phase Ⅰ trial.J Clin Oneol,2000,18(11):335-360
[49]国虹,陈亮,张博,杨猛,崔清枫．依西美坦治疗绝经后晚期乳腺癌Ⅱ期临床观察．中国医刊,2008,43(1)：45-46
[50]Cobleigh MA,Vogel CL,Tripathy D,et al.Mul-tinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressioning metastatic breast cancer that has progressed after chemotherapy for metastatic disease.J Clin Oncol,1999,117:2639-2648
[51]Vogel C,Cobleigh MA,Tripathy Det al.Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-over ex-pressing metastatic breast cancer.J Clin Oncol.2002,20(3):71926
[52]SlamonD,Leyland-JonesB,Shak Setal.Use ofchemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer thatoverexpressesHER2.N Engl JMed,2001,344(11):783-92
[53]Pegram MD,PienkowskiT,NorthfehDW,et al.Results oftwo open-label, muhicenter phase Ⅱ studies of docetaxel.Platinum salts,and trastuzumab in HER-2 positive advanced breast cancer.J Natl Cancer Inst,2004,96:759-769
[54]Pegram M,Forbes J,Pienkowski T,et al.BCIRG 007:First overall survival analysis of randomized phase 11I trial of trastuzumab plus docetax el with or without carboplatin as first line therapy in HER-2 amplified metastatic breast cancer(MBC)/2007 ASCO Annual Meeting.VA,Alexandria:ASCOPress Center,2007:1008
[55]Morabito A,Longo R,Gattuso D,et al.Trastuzumab incombination with gemcitab ine and vinorelbine as second-line therapy for HER-2 / neu overexpressing metastatic breast cancer.Oncol Rep,2006,16:393-398
[56]Papaldo P.Fabi A,Ferretti Get al.Phase Ⅱ study onmetastatic breast cancer patients treated with weekly vi-norelbine with or without trastuzumab according to HER2 expression:changing the natural history of HER2-positive disease.Ann Oncol,2006,17(4):630-636
[57]AlbainK,ElledgeR,GradisharWJ,et al.Open-label,phase Ⅱ,multicenter trial of ZD 1839(Iressa) in patients with advanced breast cancer.Breast Cancer Res Treat,2002,76:S33(abstr 20)
[58]Lackey KE.Lessons from the drug discovery of lapatinib,a dual HErbB1/2tyrosine kinase inhibitor.Curr Top Med Chem,2006,6(5):435-460
[59]Nelson MH,Dolder CR.Lapatinib:a novel dual tyrosine kinase inhibitor with activity in solid tumors.Ann Pharmacother,2006,40(2):261-269
[60]Cobleigh MA,Miller K,Langmuir VK,et al.Phase Ⅱ dose escalation trial of Avastin(bevacizumab) in women with previously treated metastatic breast cancer.Breast Cancer Res Treat,2001,69:301(abstr)
[61]Kadlamani V,O Regan RM,New targeted therapies in breast cancer,Semin Oncol,2004(Suppl4),31(2):20-25
[1]中国中西医结合研究会老年病中医专业委员.中医虚证辨证参考标准.中西医结合杂志,1986,10:598
[2]中国中西医结合研究会活血化瘀专业委员会.血瘀证诊断标准.中西医结合杂志,1987,7(3):129
[3]中医病证诊断疗效标准编审委员会.中医病证诊断疗效标准.江苏:南京大学出版社,1994,36
[4]冷方南.中医证候辩证规范.北京:人民卫生出版社,1991,40
[5]印会河.中医基础理论.上海:上海科学技术出版社,1984,29-46
[6]赵远红.恶性肿瘤“温药和之”解析.新中医,2008,40(7)
[7]Vanagthoven A.Characterization of T cell surface glycoproteins T and T present on all human peripheral T lymphocytes and functionally nature thymocytes.Eur J Immun,1981,11:18
[8]Rein herz EL.The differentiation and founction of human T lymphocytes:a review.Cell,1985,9:821
[9]Iwitter M.Do suppressor T cells become helper T cell Immunology Today,1984,5:61
[10]Hadjipetron LK.Restoration of immunosupression in lung cancer by normal serum.J Clin Immunol,1985,16:149
[11]何岚,徐月红,刘亚萍.抗肿瘤中药复方免疫调节作用的实验研究思路.中医药学报,2003,31(5):16-17
[12]周天红.中药的抗肿瘤药理概述.时珍国医国药,2003,14(11):699-700
[13]王志良,樊青霞,王冬青等.消化系恶性肿瘤脾虚证患者 T 淋巴细胞亚群分布关系的初步观察.河南肿瘤学杂志,1994,7(2):111-113
[14]王彦,林求诚.恶性肿瘤中医虚证与免疫功能状态关系临床研究.实用中西医结合杂志,1997,10(21):2060-2061
[15]何岚,徐月红,刘亚萍.抗肿瘤中药复方免疫调节作用的实验研究思路.中医药学报,2003,31(5):16-17
[16]周天红.中药的抗肿瘤药理概述.时珍国医国药,2003,14(11):699-700
[17]MakrisA,PowlesTJ,AllredDC,etal.Quantit changes in cytological molecular markers primary medicaltreatment of breastcancer:APilot study.Breast Cancer Res Treat,1999,53(1):51-59
[18]童彩玲.中药联合三苯氧胺周期治疗乳腺增生症的实验研究.中国中医药信息杂志,2004,11(10):865-866
[19]沈镇宙,邵志敏.乳腺肿瘤学,上海科技出版社,2005:30
[2]李春杰,魏品康,施俊,刘龙,巨大维.恶性肿瘤从痰论治的研究思路与方法.解放军保健医学杂志,2007,9(4):241-242
[3]杨浩.癌症论.中国民族民间医药,2008,17(3):57-58
[4]陈健民.癌症患者血液高凝状态与活血化瘀治疗.中国中西医结合杂志,1985,5(2):89-91
[5]薛晓红,陈红风,陆德铭.陆德铭教授治疗乳房病的学术思想及临证经验.中医药研究,2002,18(5):1-2
[6]徐力.王居祥主任医师治疗乳腺癌经验举隅.南京中医药大学学报,2007,23(1):54
[7]李树玲.乳腺肿瘤学.科学技术文献出版社,2000,535-537
[8]尚德俊.新编中医外科学.济南出版社,1995,103
[9]陆德铭.实用中医乳房病学.上海中医学院出版社,1993,29
[10]郁仁存.中医肿瘤学(上册).科学出版社,1997
[11]王玉章.乳岩.北京中医,1993,(3):59-60
[12]周宝琴.治疗乳腺癌的临床体会.吉林中医药,1985,(4):17-18
[13]田劭丹,李忠.乳腺癌的中西医结合诊治.中国临床医生杂志,2007,35(5):17-18
[14]王宗发.乳腺癌临床分型证治.中华现代医学与临床,2005,3(2):69-70
[15]刘胜,陆德铭,唐汉钧.302例乳腺癌术后患者辨证分型标准的临床研究.中国医药报,2004,19(11):666-668
[16]徐杰男,阙华发.乳腺癌术后患者241例辨证分型探析.浙江中医杂志2005,40(12):530-532
[17]唐汉钧.乳腺癌的中医临床与实验研究.中医药学刊,2003,21(2):168-172
[18]Anthoy L,David JK.Cancer,Coagulation,and Anticoagulation.Oncologist,1999,443
[19]唐汉钧.乳腺癌术后的临证思考.上海中医药杂志,2005,39(1):3-5
[20]司徒红林,陈前军,朱华宇.林毅教授辨治乳腺癌经验介绍.新中医,2008,40(7):5-6
[21]王晓戎,李平,吴志丽.肿瘤化疗后中医证候学特征调查研究.山东中医杂志,2006,25(1):18-20
[22]顾群浩,蔡照弟,张胜华.乳腺癌辨证分型与雌孕激素受体的相关性分析.辽宁中医杂志,2004,31(6):463-464
[23]孙红,李萍萍.乳腺癌中医证候分类与预后相关性的初步研究.中国中医基础医学杂志,2003,9(2):72-73
[24]李萍萍,孙红,史桂芝等.移植瘤的血液流变学与活血化瘀中药作用的研究.肿瘤,2000,20(3):44
[25]张瑾,吴咸中,李特.乳腺癌中西医结合辨证分型研究.中国中西医结合外科杂志, 2001,7(1):13-15
[26]PapantoniouVJ,SouvatzoglouMA,ValotassiouVJ,eta.1 Relationship of cell proliferation(Ki-67) to 99mTc2(V)DMSA uptake in breast cancer[J].Breast CancerRes,2004,6(2):56262
[27]Mast ronardi L,GuiducciA,Puzzilli F.Lack of correlation be-tween Ki267labelling index and tumor size ofanteriorpi2 tuitary adenomas.BMC Cancer,2001,31(12):1232130
[28]宋爱莉,殷玉琨.乳腺癌术前中医辨证与肿瘤增殖因子相关性研究.中华中医药学刊,2008,26(5):907-908
[29]郭俊骐,郭卉艳,李兵.名老中医石玉林治疗乳腺癌骨转移30例.吉林中医药,1998,(2):3-4
[30]李俊玉.癌毒的病因病机及临证治法的概念探析.江西中医药,2005,36(8):14-15
[31]卢雯平,林洪生.160例乳腺癌术后血行转移患者中医辨证分型的研究.临床肿瘤学杂志,2006,11(6):425-426
[32]秦海洗.唐汉钧教授治疗乳腺癌辨证思路与用药经验.中西医结合学报,2004,2(4):297-298
[33]欧阳华强,黄雯霞,刘鲁明.消瘕方治疗乳腺癌术后110例的临床观察.上海中医药杂志,2006,40(6):50-51
[34]许宇飞,张成智.乳腺癌 X 线征象与中医证型关系分析.中医药信息,1999,16(1):39-40
[35]张昌政,翠玲.肝郁痰凝型乳腺癌的钼靶 X 线表现及病理分析.山西中医,2006,22(6):50-51
[36]黄勇,张延伟,李健萍,李圆.乳腺癌 MR 征象与中医证型关系观察.新中医,2008,40(8):35-38
[37]周红,郭亚东等.中药治疗晚期乳腺癌9例报道.实用肿瘤学杂志,1998,2(1):59-60
[38]王庆才.蟾雄膏外敷治疗癌性疼痛103例.陕西中医,1993,14(5):195
[39]肖毅良,杨邵波.菊藻丸治疗乳癌术后转移的临床研究.中国中西医结合外科杂志,1998,4(5):202.
[40]刘抒玉,殷东风.中医药治疗乳腺癌92例临床观察.吉林中医药,2008,28(5):333-334
[41]吴少华,张促海,赵健斌.补骨脂素体内外抗癌活性的实验研究.中国中药杂志,1998,23(5):303
[42]赵勇,崔正言,张玲等.淫羊霍甙对人急性早幼粒白血病细胞分化的影响.中华肿瘤杂志,1997,19(1):53
[43]李薇,易永林.人参茎叶总皂甙对人白血病细胞株的诱导作用.山西白血病,1992:1(1):34
[44]刘胜.“乳宁冲剂”抑制 DMBA 诱发大鼠乳腺癌模型的实验研究.亚洲医药,1997,3(5):95
[45]孙斌,瞿伟菁,柏忠江.蒺藜皂苷对乳腺癌细胞 Bcap-37 的体外抑制作用.中药材,2003,26(2):104-106
[46]张维文,黎银燕,张贵平等.熊果酸诱导人乳腺癌细胞 MCF-7 凋亡的实验研究.中药材,2005,28(4):297-300
[47]曲志博,陈炜,郭化鑫等.三氧化二砷对乳腺癌作用的研究进展.中华实验外科杂志,2006,23(5):639-640
[48]余素清,刘京生,韩彩芝.复方绞股蓝提高乳腺癌患者 NK 细胞活性.中医药研究,1997,13(4):7-8
[49]杨丽萍,孙士玲.中药配合术前化疗治疗乳腺癌临床研究.河南中医学院学报,2004,4(19):40
[50]林军梅.补阳还五汤治疗乳腺癌术后上肢肿胀36例.浙江中医学院学报,1997,21(5):38
[51]樊风英,周松阳.补阳还五汤加减治疗乳腺癌术后上肢水肿19例体会.甘肃中医,2002,15(6):25-26
[52]王志华.中药治疗乳腺癌术后上肢肿胀30例.中国中西医结合外科杂志,2008,14(1):57-58
[53]孙鲁.复方丹参注射液静滴防治乳腺癌术后并发症的临床观察.山东医药,1999,39(24):55
[54]孙德娟,黄克江,鲍维珍.生肌玉红膏治疗乳腺癌术后皮瓣坏死26例体会.黑龙江医学,2006,30(7):553
[55]蔡炳,郭勤,郭智涛等.生肌玉红膏对乳腺癌术后皮瓣坏死溃疡的疗效观察.中医外治杂志,1997,(5):11
[56]洪宋贞,林毅,司徒红林.龟鹿二仙丹加味治疗乳腺癌化疗后骨髓抑制的研究.新中医,2005,37(1):32-34
[57]韩娅.健脾益肾中药防治乳腺癌放疗血液毒性作用的观察.中医药临床杂志,2005,17(1):25-26
[58]张宏,李国康.增髓汤对乳腺癌术后化疗改善骨髓抑制的研究.实用医学杂志,2005,21(13):1481-1482.
[59]李云著,李志革,黄秉琰.四磨汤治疗化疗所致的胃肠道症状27例总结.湖南中医杂志,1997,13(4):5
[60]吴雪卿,刘胜,高尚璞.乳宁Ⅱ号对 MCF-7 实验研究移植瘤的抑瘤作用及对乳腺癌相关蛋白的影响.中国中西医结合外科杂志,2004,10(2):99-102
[61]张永军,张在典等.中药熏洗防治希罗达所致手足综合征25例.现代中西医结合杂志,2008,17(10):1495
[62]李福莲,张克伟,张春生,高玲,菅福琴.自制中药洗剂防治乳腺癌化疗脱发30例效果观察.齐鲁护理杂志,2007,13(13):24-25
[63]张利伟,赵娟.中西医结合治疗放射性肺炎的临床研究.中国实用医药.2008,3(24):112-113
[64]廖震,胡春申.润肺清热方治疗放射性肺炎60例疗效观察.中国中医急症,2008,17(1):18-19
[65]黄智芬,黎汉忠,施智严等.逍遥散化疗并用治疗乳腺癌32例分析.中医药学刊,2003,21(6):1017
[66]徐力,龚蔚.疏肝化瘀解毒方联合 TE 方案治疗乳腺癌15例.南京中医药大学学报,2008,24(1):66-67
[67]孙靖中.中医药在乳腺癌围手术期的应用研究.华夏医药,2006,33(8):25
[68]郝淑芳.中药配合来曲唑治疗晚期乳腺癌临床观察.中医药学刊,2004,22(11):2089
[69]袁灿宇,张丽蓓.CMFA 化疗方案配合中药治疗晚期乳腺癌31例近期疗效观察.河南中医,2004,24(5):42-43
[70]张洪亮,王宁.乳腺癌辨治篡要.新疆中医药,2001,19(3):3-4
[71]欧阳华强,黄雯霞,刘鲁明.乳腺癌肝转移治疗进展.实用癌症杂志,2005,20(4):442-445
[72]周菊英.中西医结合治疗晚期乳腺癌86例临床观察.山西中医,2000,16(6):30-31
[73]冯春霞,梁蔚文.陈玉坤运用中医药治疗肿瘤经验析义.辽宁中医杂志,2005,32(9),883-884
[1]Bonadonna G,Valagussa P,BrambillaC,et al.Primary chemotherapy in operable breast cancer:Eight-year experience at the Milan Cancer Institute.J Clin Oncol,1998,16:93-100
[2]EllisP,Smith I,Ashley S,et al.Clinical prognostic and predictive factors for primary chemotherapy in operable breast cancer.J Clin Oncol,1998,16:107
[3]Van Praagh I,Cure H,Leduc B,et al.Efficacy of a primary chemotherapy regimen combining vinorelbine,epirubicin,and methotrexate(VEM) as neoadjuvant treatment in 89 patients with operable breast cancer.Oncologist,2002,7(5):418-423
[4]Bonadonna G,Valgussa P,Moliterni A,et al.Adjuvant cyclophosphamide,methotrexate and fluorouracil in node-positive breast cancer:the results of 20 year follow-up.N Engl J Med,1995,332:901-906
[5]Levine MN,Bramwell VH,Pritchard KI,et al:Randomized trial of intensive cyclophosphamide,epirubicin and fluorouracil chemotherapy compared with cyclophosphamide,methotrexate and fluorouracil in premenopausal women with node-positive breast cancer.National Cancer Institute of Canada Clinical Trials Group.J Clin Oncol,1998,16:2651-2658
[6]Henderson IC,Berry DA,Demetri GD,et al.Imp roved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer[J].J Clin Oncol,2003,21(6):976-983
[7]Henderson IC,Berry DA,Demetri GD,et al.Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an ad-juvant chemotherapy regimenforpatientswithnode-positive primary breastcancer.J Clin Oncol,2003,21(6):976-983
[8]MamounasEP,BryantJ,Lembersky B,etal.Paclitaxelafterdoxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer:results from NSABP B-28.JClin Oncol,2005,23(16):3686-3696
[9]Boer K,Lang I,Juhos E,et al.Adjuvant therapy ofbreast cancer with docetaxel-containing combination (TAC).Pathol OncolRes,2003,9(3):166-169
[10]Marc LC,Donstance C,et al.Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer:First Report on Intergroup Trial CALGB 9741.J Clin Oncol,2003,21:1431-149
[11]Sledge MD,Oneil A,Thor AD,et.al.Pilot trial of paclitaxel-Herceptin adjuvant therapy for early stage breast cancer(E2198).Breast cancer Res Treat,2001,69:209
[12]Jones SE,Erban J,Overmoyer B,et al.Randomized phaseⅢ study of docetaxelcompared withpaclitaxel inmetastaticbreastcancer.JClin Oncol,2005,23(24):5542-5551
[13]Blum JL,Jones SE,Buzdar AU,et al.Multicenter phase Ⅱ study of capecitabinein paclitaxel-refractory metastaticbreastcancer.Clin Oncol,1999,17(2):485-493
[14]Blackstein M,Vogel CL,Ambinder R,et al.Gemcitabineas first-line therapyin patients with metastatic breastcancer:a phase Ⅱ trial.Oncology,2002,62(1):2-8
[15]杨军丛,曹月辉,苑丽华,陈忠云,李志霞.EAP 方案治疗晚期乳腺癌38例的临床观察.中国实用医药,2007,2(4):37
[16]王佳玉,徐兵河,张频,李青.紫杉醇联合顺铂治疗57例晚期乳腺癌的临床疗效分析.中华肿瘤防治杂志,2007,14(9):695-697
[17]王红.紫杉醇联合阿霉素治疗晚期乳腺癌疗效观察.中国肿瘤临床与康复,2007,14(1):50-51
[18]刘天亮,吴云.多西紫杉醇联合顺铂治疗晚期乳腺癌21例分析.中国误诊学杂志,2008,8(3).707-708
[19]王朝阳,杨帆,李桂生,黄海欣.泰索帝联合顺铂治疗26例葸环类耐药性晚期乳腺癌临床观察.实用医学杂志,2008,24(1):102-103
[20]吴星娆.卡培他滨在乳腺癌治疗中的临床应用.国际肿瘤学杂志2007,34(3):210-212
[21]李文欢.卡培他滨单药治疗葸环类和紫杉醇类耐药的晚期乳腺25例.中华肿瘤防治杂志,2007,14(3):216-217
[22]Seidman AD.Gemcitabine as single-agent therapy in themanage-ment of advanced breast cancer.Oncology,2001,15(2)(Supp13):11-14
[23]张志强,江泽飞,宋三泰.吉西他滨在乳腺癌化疗中的临床应用.国外医学肿瘤学分册,2003,30(2):132-135
[24]Mohran TZ.Gemcitabine and Cisplatin combination chemothera-py as a first-line treatment in patients with metastatic breastcance.JEgyptNatl Canc Inst,2004,16(1):8-14
[25]NagourneyRA,Link JS,Blitzer J,et al Gemcitabline plus cispla-tin repeating doublet therapy in previously treated,relapsed breast cancer patients.JClinOnco,12000,18(11):224-2249
[26]徐兵河,李凯,刘端琪.吉西他滨联合顺铂治50例蒽环类耐药的晚期乳腺癌.中国癌症杂志,2003,13(6):579-81
[27]刘明恒,陈旭.吉西他滨联合顺铂治疗 HER2 阳性转移性乳腺癌疗效观察.实用癌症杂志,2007,22(1):75-76
[28]黄普文,卢凯华,束永前,王榕生,朱陵君,王建,刘凌翔,穆庆霞.以吉西他滨为主的联合化疗方案治疗晚期乳腺癌的疗效评价.临床肿瘤学杂志,2007,12(2):94-96
[29]蓝玉宏,魏巍,长春瑞滨联合顺铂治疗晚期乳腺癌的疗效及毒副反应观察.现代预防医学,2007,34(4):879-880
[30]李宗宪,刘秀萍,丰建萍。NP 方案治疗转移性乳腺癌临床观察。中国肿瘤临床与康复,2007,14(1):53-55
[31]张爱琴,郭根法.去甲长春碱联合顺铂治疗转移性乳腺癌.癌症,2001,20(12):1408-1410
[32]孙燕,张湘如,张和平.去甲长春花碱Ⅲ期临床试用结果.中国新药杂志,1998,7(4):262-265
[33]唐域.NP 方案治疗晚期乳腺癌临床观察.WorldHealthDigest,2008,5(3):67-68
[34]EBCTCG(Early Breast Cancer Trialists Collaborative Group) Early Breast Cancer Trialists Collaborative Group.Tamoxifen for early breast cancer:an overview of the randomized trials.Lancet,1998,351:1451-1467
[35]Albain KS,Green SJ,Racsin PM,et al.Adjuvant chemohormonal therapy for primary breast cancer should be sequential inwtead of concurrent:Initial results from intergroup trail 0100(SWOG-8814).Proc AM Soc Clin Oncol,2002,21:37
[36]ODRegan R M.Chemoprevention of breast cancer.Lancet,2006,367(9520):1382-1383
[37]Nabholtz J M,Buzdar A,Pollak M,et al.Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women:results of a North American multicenterrandomized trial,Arimidex Study Group.J Clin Oncol,2000,18(22):3758-3767
[38]Howell A,Cuzick J,Baum M,et al.Results of the ATAC(arimidex,tamoxifen,alone or in combination) trial after completion of 5 yearsD adjuvant treatment for breast cancer.Lancet,2005,365(9453):60-62
[39]Jakesz R,Jonat W,Gnant M,et al.Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 yearsD adjuvant tamoxifen:combined results Of ABCSG trial 8 and ARNO 95trial.Lancet,2005,366(9484):455-462
[40]Mouridsen H,Gershanovich M,Sun Y,et al.Superior efficacy of letrozoleversus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer:results of a phase Ⅲstudy of the International Letrozole Breast Cancer Group,J ClinOncol,2001,19(10):2596-2606
[41]Thurlimann B,Keshaviah A,Coates A S,et al.A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.N Engl J Med,2005,353(26):2747-2757
[42]Goss P E,Ingle J N,Martino S,et al.Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer:updated findings from NCIC CTG MA 17.J Natl Cancer Inst,2005,97(17):1262-1271
[43]Paridaens R,Dirix L,Lohrisch C,etal.Mature results of a randomized phase Ⅱ multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer.Ann Oncol,2003,14 (9):1391-1398
[44]Milla Santos A,Milla L,Portella J,et al.Anastrozole versus ta-moxifen as first-line therapy in postm enopausal patients with hormone-dependent advanced breast cancer,-a prospective,random-ized,phaselllstudy.Am J Clin Oncol,2003,26(3):317-322
[45]Thurlimann B,Hess D,Koberle D,et al..Anastrozole(Arimidex)versus tamoxifen as first-line therapy in postm enopausal women with advanced breast cancer:results of the double-blind Crossover SAKK trial 21/9522a sub2study of the TARGET (Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability)trial.Breast Cancer Res Treat,2004,85(3):247-254
[46]BuzdarA,Douma J,DavidsonN,et al.Phase HI,multicenter,dou-ble-blind.randomized study of letrozole,an aromatase inhibitor,for advanced breast cancer versus megestrol acetate.J Clin On-col,2001,19(14):2234-2244
[47]Paridaens R,Dirix L,Lohrisch C,et al.Mature results of a ran-domized phase Ⅱ multicenter study of exemestane versus tamox-ifen as first-line hormone therapy for postmenopausal women-with metastatic breast cancer.Ann Oncol,2003,14(9):1391-1398
[48]Lonning PE,Bajetta E,Murray R,etal.Activity of exemestane in metastatic breast cancer after failure of nonsteroidal arom atase inhibitor:a phase Ⅰ trial.J Clin Oneol,2000,18(11):335-360
[49]国虹,陈亮,张博,杨猛,崔清枫．依西美坦治疗绝经后晚期乳腺癌Ⅱ期临床观察．中国医刊,2008,43(1)：45-46
[50]Cobleigh MA,Vogel CL,Tripathy D,et al.Mul-tinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressioning metastatic breast cancer that has progressed after chemotherapy for metastatic disease.J Clin Oncol,1999,117:2639-2648
[51]Vogel C,Cobleigh MA,Tripathy Det al.Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-over ex-pressing metastatic breast cancer.J Clin Oncol.2002,20(3):71926
[52]SlamonD,Leyland-JonesB,Shak Setal.Use ofchemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer thatoverexpressesHER2.N Engl JMed,2001,344(11):783-92
[53]Pegram MD,PienkowskiT,NorthfehDW,et al.Results oftwo open-label, muhicenter phase Ⅱ studies of docetaxel.Platinum salts,and trastuzumab in HER-2 positive advanced breast cancer.J Natl Cancer Inst,2004,96:759-769
[54]Pegram M,Forbes J,Pienkowski T,et al.BCIRG 007:First overall survival analysis of randomized phase 11I trial of trastuzumab plus docetax el with or without carboplatin as first line therapy in HER-2 amplified metastatic breast cancer(MBC)/2007 ASCO Annual Meeting.VA,Alexandria:ASCOPress Center,2007:1008
[55]Morabito A,Longo R,Gattuso D,et al.Trastuzumab incombination with gemcitab ine and vinorelbine as second-line therapy for HER-2 / neu overexpressing metastatic breast cancer.Oncol Rep,2006,16:393-398
[56]Papaldo P.Fabi A,Ferretti Get al.Phase Ⅱ study onmetastatic breast cancer patients treated with weekly vi-norelbine with or without trastuzumab according to HER2 expression:changing the natural history of HER2-positive disease.Ann Oncol,2006,17(4):630-636
[57]AlbainK,ElledgeR,GradisharWJ,et al.Open-label,phase Ⅱ,multicenter trial of ZD 1839(Iressa) in patients with advanced breast cancer.Breast Cancer Res Treat,2002,76:S33(abstr 20)
[58]Lackey KE.Lessons from the drug discovery of lapatinib,a dual HErbB1/2tyrosine kinase inhibitor.Curr Top Med Chem,2006,6(5):435-460
[59]Nelson MH,Dolder CR.Lapatinib:a novel dual tyrosine kinase inhibitor with activity in solid tumors.Ann Pharmacother,2006,40(2):261-269
[60]Cobleigh MA,Miller K,Langmuir VK,et al.Phase Ⅱ dose escalation trial of Avastin(bevacizumab) in women with previously treated metastatic breast cancer.Breast Cancer Res Treat,2001,69:301(abstr)
[61]Kadlamani V,O Regan RM,New targeted therapies in breast cancer,Semin Oncol,2004(Suppl4),31(2):20-25
[1]中国中西医结合研究会老年病中医专业委员.中医虚证辨证参考标准.中西医结合杂志,1986,10:598
[2]中国中西医结合研究会活血化瘀专业委员会.血瘀证诊断标准.中西医结合杂志,1987,7(3):129
[3]中医病证诊断疗效标准编审委员会.中医病证诊断疗效标准.江苏:南京大学出版社,1994,36
[4]冷方南.中医证候辩证规范.北京:人民卫生出版社,1991,40
[5]印会河.中医基础理论.上海:上海科学技术出版社,1984,29-46
[6]赵远红.恶性肿瘤“温药和之”解析.新中医,2008,40(7)
[7]Vanagthoven A.Characterization of T cell surface glycoproteins T and T present on all human peripheral T lymphocytes and functionally nature thymocytes.Eur J Immun,1981,11:18
[8]Rein herz EL.The differentiation and founction of human T lymphocytes:a review.Cell,1985,9:821
[9]Iwitter M.Do suppressor T cells become helper T cell Immunology Today,1984,5:61
[10]Hadjipetron LK.Restoration of immunosupression in lung cancer by normal serum.J Clin Immunol,1985,16:149
[11]何岚,徐月红,刘亚萍.抗肿瘤中药复方免疫调节作用的实验研究思路.中医药学报,2003,31(5):16-17
[12]周天红.中药的抗肿瘤药理概述.时珍国医国药,2003,14(11):699-700
[13]王志良,樊青霞,王冬青等.消化系恶性肿瘤脾虚证患者 T 淋巴细胞亚群分布关系的初步观察.河南肿瘤学杂志,1994,7(2):111-113
[14]王彦,林求诚.恶性肿瘤中医虚证与免疫功能状态关系临床研究.实用中西医结合杂志,1997,10(21):2060-2061
[15]何岚,徐月红,刘亚萍.抗肿瘤中药复方免疫调节作用的实验研究思路.中医药学报,2003,31(5):16-17
[16]周天红.中药的抗肿瘤药理概述.时珍国医国药,2003,14(11):699-700
[17]MakrisA,PowlesTJ,AllredDC,etal.Quantit changes in cytological molecular markers primary medicaltreatment of breastcancer:APilot study.Breast Cancer Res Treat,1999,53(1):51-59
[18]童彩玲.中药联合三苯氧胺周期治疗乳腺增生症的实验研究.中国中医药信息杂志,2004,11(10):865-866
[19]沈镇宙,邵志敏.乳腺肿瘤学,上海科技出版社,2005:30